Hodgkin’s lymphoma, registry, ABVD, BEACOPP, long-term toxicity, chemotherapy-induced cardiotoxicity, secondary malignanciesлимфома Ходжкина, регистр, режим ABVD, режим BEACOPP, отдаленные последствия химиотерапии, антрациклиновая кардиотоксичность, вторые опухоли1.1. Zubrod C. G. Historic milestones in curative chemotherapy. Semin Oncol1979;6(4):490–505. PMID: 394331.Zubrod C. G. Historic milestones in curative chemotherapy. Semin Oncol1979;6(4):490–505. PMID: 394331.2.2. De Vita V. T. Jr, Simon R. M., Hubbard S. M. et al. Curability of advanced Hodgkin’s disease with chemotherapy. Longterm follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980;92(5):587–95. PMID: 6892984.De Vita V. T. Jr, Simon R. M., Hubbard S. M. et al. Curability of advanced Hodgkin’s disease with chemotherapy. Longterm follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980;92(5):587–95. PMID: 6892984.3.3. Evens A. M., Hutchings M., Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 2008;5(9):543–56. DOI: 10.1038/ncponc1186.Evens A. M., Hutchings M., Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 2008;5(9):543–56. DOI: 10.1038/ncponc1186.4.4. Kimby E., Brandt L., Nygren P., Glimelius B. SBU-group. A systematic overview of chemotherapy effects in Hodgkin’s disease. Acta Oncol 2001; 40(2–3):185–97. PMID: 11441932.Kimby E., Brandt L., Nygren P., Glimelius B. SBU-group. A systematic overview of chemotherapy effects in Hodgkin’s disease. Acta Oncol 2001; 40(2–3):185–97. PMID: 11441932.5.5. Macmahon B. Epidemiological evidence of the nature of Hodgkin’s disease. Cancer 1957;10(5):1045–54. PMID: 13472655.Macmahon B. Epidemiological evidence of the nature of Hodgkin’s disease. Cancer 1957;10(5):1045–54. PMID: 13472655.6.6. Edgren G., Liang L., Adami H. O., Chang E. T. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol 2012;27(3): 187–96. DOI: 10.1007/s10654-011-9647-5.Edgren G., Liang L., Adami H. O., Chang E. T. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol 2012;27(3): 187–96. DOI: 10.1007/s10654-011-9647-5.7.7. Chen Y. T., Zheng T., Chou M. C. et al. The increase of Hodgkin’s disease incidence among young adults. Experience in Connecticut, 1935–1992. Cancer 1997;79(11):2209–18. PMID: 9179069.Chen Y. T., Zheng T., Chou M. C. et al. The increase of Hodgkin’s disease incidence among young adults. Experience in Connecticut, 1935–1992. Cancer 1997;79(11):2209–18. PMID: 9179069.8.8. Diehl V. et al. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program 2003;225–47.Diehl V. et al. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program 2003;225–47.9.9. Herbst C., Rehan F. A., Brillant C. et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica 2010;95(3):494–500. DOI: 10.3324/haematol.2009.015644.Herbst C., Rehan F. A., Brillant C. et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica 2010;95(3):494–500. DOI: 10.3324/haematol.2009.015644.10.10. Skoetz N., Trelle S., Rancea M. et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013;14(10): 943–52. DOI: 10.1016/S1470-2045(13)70341-3.Skoetz N., Trelle S., Rancea M. et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013;14(10): 943–52. DOI: 10.1016/S1470-2045(13)70341-3.11.11. Swerdlow A. J., Higgins C. D., Smith P. et al. Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a collaborative British cohort study. J Clin Oncol 2011;29(31):4096–104. DOI: 10.1200/JCO.2011.34.8268.Swerdlow A. J., Higgins C. D., Smith P. et al. Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a collaborative British cohort study. J Clin Oncol 2011;29(31):4096–104. DOI: 10.1200/JCO.2011.34.8268.12.12. Dores G. M., Metayer C., Curtis R. E. et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20(16): 3484–94. PMID: 12177110.Dores G. M., Metayer C., Curtis R. E. et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20(16): 3484–94. PMID: 12177110.13.13. Castellino S. M., Geiger A. M., Mertens A. C. et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011;117(6):1806–16. DOI: 10.1182/blood-2010-04-278796.Castellino S. M., Geiger A. M., Mertens A. C. et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011;117(6):1806–16. DOI: 10.1182/blood-2010-04-278796.14.14. Behringer K., Mueller H., Goergen H. et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013;31(2):231–9. DOI: 10.1200/JCO.2012.44.3721.Behringer K., Mueller H., Goergen H. et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013;31(2):231–9. DOI: 10.1200/JCO.2012.44.3721.15.15. Arseneau J. C., Sponzo R. W., Levin D. L. et al. Nonlymphomatous malignant tumors complicating Hodgkin’s disease. Possible association with intensive therapy. N Engl J Med 1972;287(22):1119–22. DOI: 10.1056/NEJM197211302872204.Arseneau J. C., Sponzo R. W., Levin D. L. et al. Nonlymphomatous malignant tumors complicating Hodgkin’s disease. Possible association with intensive therapy. N Engl J Med 1972;287(22):1119–22. DOI: 10.1056/NEJM197211302872204.16.16. Boivin J. F., Hutchison G. B., Lyden M. et al. Second primary cancers following treatment of Hodgkin’s disease. J Natl Cancer Inst 1984;72(2):233–41. PMID: 6420598.Boivin J. F., Hutchison G. B., Lyden M. et al. Second primary cancers following treatment of Hodgkin’s disease. J Natl Cancer Inst 1984;72(2):233–41. PMID: 6420598.17.17. Henry-Amar M. Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin’s disease. J Natl Cancer Inst 1983;71(5):911–6. PMID: 6580491.Henry-Amar M. Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin’s disease. J Natl Cancer Inst 1983;71(5):911–6. PMID: 6580491.18.18. Tucker M. A., Coleman C. N., Cox R. S. et al. Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med 1988;318(2):76–81. DOI: 10.1056/NEJM198801143180203.Tucker M. A., Coleman C. N., Cox R. S. et al. Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med 1988;318(2):76–81. DOI: 10.1056/NEJM198801143180203.19.19. Travis L. B., Demark Wahnefried W., Allan J. M. et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10(5):289–301. DOI: 10.1038/nrclinonc.2013.41.Travis L. B., Demark Wahnefried W., Allan J. M. et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10(5):289–301. DOI: 10.1038/nrclinonc.2013.41.20.20. Franklin J., Pluetschow A., Paus M.et al. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: metaanalysis of the randomised trials. Ann Oncol 2006;17(12):1749–60. DOI: 10.1093/annonc/mdl302.Franklin J., Pluetschow A., Paus M.et al. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: metaanalysis of the randomised trials. Ann Oncol 2006;17(12):1749–60. DOI: 10.1093/annonc/mdl302.21.21. Simbre I. V., Adams M. J., Deshpande S. S. et al. Cardiomyopathy Caused by Antineoplastic Therapies. Curr Treat Options Cardiovasc Med 2001;3(6):493–505. PMID: 11696269.Simbre I. V., Adams M. J., Deshpande S. S. et al. Cardiomyopathy Caused by Antineoplastic Therapies. Curr Treat Options Cardiovasc Med 2001;3(6):493–505. PMID: 11696269.22.22. Krischer J. P., Epstein S., Cuthbertson D. D. et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15(4):1544–52. PMID: 9193351.Krischer J. P., Epstein S., Cuthbertson D. D. et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15(4):1544–52. PMID: 9193351.23.23. Lipshultz S. E., Lipsitz S. R., Mone S. M. et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332(26):1738–43. DOI: 10.1056/NEJM199506293322602.Lipshultz S. E., Lipsitz S. R., Mone S. M. et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332(26):1738–43. DOI: 10.1056/NEJM199506293322602.24.24. Aminkeng F., Ross C. J., Rassekh S. R. et al. Recommendations for genetic testing to reduce the incidence of anthracyclineinduced cardiotoxicity. Br J Clin Pharmacol 2016;82(3):683–95. DOI: 10.1111/bcp.13008.Aminkeng F., Ross C. J., Rassekh S. R. et al. Recommendations for genetic testing to reduce the incidence of anthracyclineinduced cardiotoxicity. Br J Clin Pharmacol 2016;82(3):683–95. DOI: 10.1111/bcp.13008.25.25. Blanco J. G., Sun C. L., Landier W. et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes – a report from the Children’s Oncology Group. J Clin Oncol 2012;30(13):1415–21. DOI: 10.1200/JCO.2011.34.8987.Blanco J. G., Sun C. L., Landier W. et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes – a report from the Children’s Oncology Group. J Clin Oncol 2012;30(13):1415–21. DOI: 10.1200/JCO.2011.34.8987.26.26. Lipshultz S. E., Lipsitz S. R., Kutok J. L. et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicintreated survivors of childhood high-risk leukemia. Cancer 2013;119(19):3555–62. DOI: 10.1002/cncr.28256.Lipshultz S. E., Lipsitz S. R., Kutok J. L. et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicintreated survivors of childhood high-risk leukemia. Cancer 2013;119(19):3555–62. DOI: 10.1002/cncr.28256.27.27. Moser E. C., Noordijk E. M., van Leeuwen F. E. et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006;107(7):2912–9. DOI: 10.1182/blood-2005-08-3392.Moser E. C., Noordijk E. M., van Leeuwen F. E. et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006;107(7):2912–9. DOI: 10.1182/blood-2005-08-3392.28.28. Schultz-Hector S., Trott K. R. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 2007;67(1):10–8. DOI: 10.1016/j.ijrobp. 2006.08.071.Schultz-Hector S., Trott K. R. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 2007;67(1):10–8. DOI: 10.1016/j.ijrobp. 2006.08.071.29.29. Gagliardi G., Constine L. S., Moiseenko V. et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl): 77–85. DOI: 10.1016/j.ijrobp.2009.04.093.Gagliardi G., Constine L. S., Moiseenko V. et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl): 77–85. DOI: 10.1016/j.ijrobp.2009.04.093.30.30. Hancock S. L., Tucker M. A., Hoppe R. T. . Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993;270(16):1949–55. PMID: 8411552.Hancock S. L., Tucker M. A., Hoppe R. T. . Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993;270(16):1949–55. PMID: 8411552.31.31. Aleman B. M., van den Belt-Dusebout A. W., De Bruin M. L. et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109(5):1878–86. DOI: 10.1182/blood-2006-07-034405.Aleman B. M., van den Belt-Dusebout A. W., De Bruin M. L. et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109(5):1878–86. DOI: 10.1182/blood-2006-07-034405.32.32. Myrehaug S., Pintilie M., Tsang R. et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supraadditive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49(8):1486–93. DOI: 10.1080/10428190802140873.Myrehaug S., Pintilie M., Tsang R. et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supraadditive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49(8):1486–93. DOI: 10.1080/10428190802140873.33.33. Kremer L. C., van Dalen E. C., Offringa M. et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001;19(1):191–6. PMID: 11134212.Kremer L. C., van Dalen E. C., Offringa M. et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001;19(1):191–6. PMID: 11134212.